Literature DB >> 17492413

[Therapy and follow-up of bladder cancer].

Daniel Meyer1, Hans-Peter Schmid, Daniel S Engeler.   

Abstract

Treatment and follow up of bladder cancer strongly depends on stage and differentiation of the tumour. Superficial bladder tumours can mostly be controlled by transurethral resection followed by early intravesical application of a chemotherapeutic agent and a further close meshed follow-up. Generally, for muscle-invasive tumours radical cystectomy is indicated, whereas organ-spearing treatment due to combined therapeutic concepts can be offered in selected cases. For advanced and metastatic tumours, despite good response of bladder cancer to chemotherapy, prognosis is still poor. However, implementation of new chemotherapeutic agents indicate a trend towards improved survival rates.

Entities:  

Mesh:

Year:  2007        PMID: 17492413     DOI: 10.1007/s10354-007-0381-2

Source DB:  PubMed          Journal:  Wien Med Wochenschr        ISSN: 0043-5341


  57 in total

1.  The pathogenesis and implications of the electrolyte imbalance in ureterosigmoidostomy.

Authors:  T A STAMEY
Journal:  Surg Gynecol Obstet       Date:  1956-12

Review 2.  Bacillus Calmette-Guérin and superficial bladder cancer. Clinical experience and mechanism of action.

Authors:  W J Catalona; T L Ratliff
Journal:  Surg Annu       Date:  1990

3.  Nordic prospective trials of radical cystectomy and neoadjuvant chemotherapy. The Nordic Cooperative Bladder Cancer Study Group.

Authors:  S Hellsten; E Rintala; R Wahlqvist; P U Malmström
Journal:  Eur Urol       Date:  1998       Impact factor: 20.096

Review 4.  The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee.

Authors:  J I Epstein; M B Amin; V R Reuter; F K Mostofi
Journal:  Am J Surg Pathol       Date:  1998-12       Impact factor: 6.394

5.  A retrospective analysis of 153 patients treated with or without intravesical bacillus Calmette-Guerin for primary stage T1 grade 3 bladder cancer: recurrence, progression and survival.

Authors:  Osama Shahin; George N Thalmann; Cyrill Rentsch; L Mazzucchelli; U E Studer
Journal:  J Urol       Date:  2003-01       Impact factor: 7.450

6.  Intravesical bacillus Calmette-Guérin therapy prevents tumor progression and death from superficial bladder cancer: ten-year follow-up of a prospective randomized trial.

Authors:  H W Herr; D M Schwalb; Z F Zhang; P C Sogani; W R Fair; W F Whitmore; H F Oettgen
Journal:  J Clin Oncol       Date:  1995-06       Impact factor: 44.544

7.  Long-term metabolic and nutritional effects of urinary diversion.

Authors:  T Davidsson; B Lindergård; W Månsson
Journal:  Urology       Date:  1995-12       Impact factor: 2.649

Review 8.  Bladder substitution.

Authors:  Jürgen E Gschwend
Journal:  Curr Opin Urol       Date:  2003-11       Impact factor: 2.309

9.  Bacillus Calmette-Guerin immunotherapy of superficial bladder cancer.

Authors:  D L Lamm; D E Thor; S C Harris; J A Reyna; V D Stogdill; H M Radwin
Journal:  J Urol       Date:  1980-07       Impact factor: 7.450

Review 10.  Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis.

Authors: 
Journal:  Lancet       Date:  2003-06-07       Impact factor: 79.321

View more
  1 in total

1.  Transurethral resection of bladder cancer on the lateral bladder wall without obturator nerve block: extent of adductor spasms using the monopolar versus bipolar technique-a prospective randomised study.

Authors:  T Gramann; C Schwab; V Zumstein; P Betschart; M Meier; H-P Schmid; D S Engeler
Journal:  World J Urol       Date:  2018-03-01       Impact factor: 4.226

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.